Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+ primary ductal breast carcinoma: A meta-analysis of microarray datasets

Effects of neoadjuvant therapies on genetic regulation of targeted pathways in ER+ primary ductal breast carcinoma: A meta-analysis of microarray datasets

Breast cancer arises as a result of multiple interactions between environmental and genetic factors. Conventionally, breast cancer is treated based on histopathological and clinical features. DNA technologies like the human genome microarray are now partially integrated into clinical practice and ar...

Full description

Bibliographic Details
Main Authors:	Sarah M. Albogami, Yousif Asiri, Abdulaziz Asiri, Alaa A. Alnefaie, Sahar Alnefaie
Format:	Article
Language:	English
Published:	Elsevier 2021-07-01
Series:	Saudi Pharmaceutical Journal
Subjects:	Chemotherapy ER+ ductal carcinoma GSR NOX4 CASP3 ERBB2 (HER2)
Online Access:	http://www.sciencedirect.com/science/article/pii/S1319016421000840

Similar Items

HER2 induces expression of leptin in human breast epithelial cells
by: Aree Moon
Published: (2012-12-01)

MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer
by: Almir G.V. Bitencourt, et al.
Published: (2020-11-01)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
by: Sasagu Kurozumi, et al.
Published: (2020-08-01)

The ERBB2 gene polymorphisms rs2643194, rs2934971, and rs1058808 are associated with increased risk of gastric cancer
by: K.C. Vázquez-Ibarra, et al.
Published: (2019-05-01)

Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma
by: Adrienne Pratti Lucarelli, et al.

Trastuzumab: updated mechanisms of action and resistance in breast cancer
by: Francois X. Claret, et al.
Published: (2012-06-01)

Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
by: Taha Heba F., et al.
Published: (2021-05-01)

Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis
by: Amir Shamshirian, et al.
Published: (2020-10-01)

Evaluation of the Prevalence of HER-2 Expression and Its Relationship with Prognostic Parameters in Colorectal Carcinoma
by: Cansu Benli Işık, et al.
Published: (2020-05-01)

Alcohol and Cancer Stem Cells
by: Mei Xu, et al.
Published: (2017-11-01)

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
by: Tameka A Bailey, et al.
Published: (2011-01-01)

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
by: Jeeyun Lee, et al.
Published: (2019-04-01)

Expression of HER2/c-erbB-2, EGFR protein in gastric carcinoma and its clinical significance
by: Cheng Guoxiong, et al.
Published: (2019-05-01)

Immunohistochemical Screening of HER2 in Canine Carcinomas: A Preliminary Study
by: Barbara Brunetti, et al.
Published: (2021-04-01)

Transcriptome and genome evolution during HER2-amplified breast neoplasia
by: Peipei Lu, et al.
Published: (2021-07-01)

Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model
by: Liliana D. Ordonez, et al.
Published: (2021-05-01)

Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast
by: Marcus Vinicius Martins de Menezes, et al.

Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
by: Takuya Osada, et al.
Published: (2018-08-01)

Estudo comparativo entre os métodos LSAB®+ e Herceptest® para a detecção de HER-2/neu em carcinoma de mama A comparative study between LSAB®+ and Herceptest® in the detection of HER-2/neu in breast carcinoma
by: Alexandre de Oliveira Sales, et al.
Published: (2004-08-01)

Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein
by: Flávia Silva Ferrini, et al.
Published: (2001-01-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
by: Sven Roßwag, et al.
Published: (2021-04-01)

Association between serum HER2/ErbB2 levels and coronary artery disease: a case–control study
by: Wen Jian, et al.
Published: (2020-03-01)

Cardiac Melanoma Metastasis with ERBB2 Gene Amplification: A Potential for Future Targeted Therapy
by: Polona Gams, et al.
Published: (2021-03-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
by: María del Mar Noblejas-López, et al.
Published: (2021-03-01)

The relationship of hormonal receptor, HER-2, and KI-67 changes after administration of anthracycline-based neoadjuvant chemotherapy with the results of histopathological grading in stage III breast cancer patients at Saiful Anwar Malang Regional Public H
by: Risal Wintoko, et al.
Published: (2019-12-01)

Breast Cancer Subtypes among Iraqi Patients: Identified By Their ER, PR and HER2 Status
by: Nada A.S. Alwan, et al.
Published: (2018-01-01)

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis
by: Márcio Debiasi, et al.
Published: (2018-05-01)

Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice
by: Kathrin Hedegger, et al.
Published: (2020-08-01)

El cáncer de mama
by: Miguel Martín, et al.
Published: (2015-06-01)

The under-appreciated promiscuity of the epidermal growth factor receptor family.
by: Sean P Kennedy, et al.
Published: (2016-08-01)

Clinicopathologic features of invasive metaplastic and micropapillary breast carcinoma: comparison with invasive ductal carcinoma of breast
by: Atif Ali Hashmi, et al.
Published: (2018-07-01)

Régulation de l’activité transcriptionnelle des récepteurs des estrogènes (ER) par le récepteur à chimiokine CXCR4 et les récepteurs à activité tyrosine kinase ErbB2 et ErbB3
by: Sauvé, Karine
Published: (2014)

Régulation de l’activité transcriptionnelle des récepteurs des estrogènes (ER) par le récepteur à chimiokine CXCR4 et les récepteurs à activité tyrosine kinase ErbB2 et ErbB3
by: Sauvé, Karine
Published: (2014)

Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective
by: Alaa Alnefaie, et al.
Published: (2020-11-01)

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination Therapy
by: Daniela Gutsch, et al.
Published: (2021-01-01)

Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer
by: Babak Nami, et al.
Published: (2021-08-01)

Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family
by: Anton Arkhipov, et al.
Published: (2013-07-01)

Assessment of HER-2 status in invasive breast cancer in Brazil
by: Victor Eduardo Arrua Arias, et al.